



ASX / MEDIA RELEASE

1st June 2016

Market Update

Sydney, Australia; 1st June 2016 – Sirtex Medical Limited (ASX:SRX) today provides an update on its second half operating performance and expectations for the 2016 financial year dose sales growth.

Sirtex has continued to achieve very strong growth in the Americas during the second half, where dose sales growth is anticipated to be in the order of 18-20% and at an identical range on a full year basis compared to the prior corresponding period (pcp). However, the outstanding performance of the Americas will not be sufficient to offset the lower than anticipated dose sales performance in the EMEA and APAC regions during the second half.

Specifically, the dose sales performance during the second half has been affected by:

- Delays in achieving product reimbursement in some important EMEA countries;
- Publication of the SIRFLOX clinical study in the *Journal of Clinical Oncology* occurring later than anticipated, which restricted sales and marketing initiatives, globally;
- A tighter funding environment within several established European markets; and
- Temporary supply disruptions in some Asian markets.

Accordingly, Sirtex has set revised full year dose sales growth guidance at 15-17% compared to the pcp versus previous guidance that dose sales would grow at least in-line with historic trends, which over the last five years represents a compound annual growth rate or CAGR of 19.7%.

Mr Gilman Wong, Chief Executive Officer of Sirtex Medical Limited commented “While we are disappointed we will be unable to achieve our FY16 guidance on dose sales growth, it is important to recognise the impacts on the business outside of the Americas are timing related. The long term growth potential of our innovative SIR-Spheres Y-90 resin microspheres product remains strong, with approximately 2% of the addressable market penetrated to date.”

Sirtex Medical will report its 2016 financial results on the 24th of August 2016.

About SIR-Spheres[®] Y-90 Resin Microspheres

SIR-Spheres Y-90 resin microspheres are a medical device used in interventional oncology and delivered via Selective Internal Radiation Therapy (SIRT), also known as radioembolisation, directly to liver tumours. SIR-Spheres Y-90 resin microspheres are approved for supply in key markets, such as the United States, European Union and Australia.

Head Office
Level 33, 101 Miller Street
North Sydney, NSW 2060
Australia

Americas
300 Unicorn Park Drive
Woburn, MA 01801
United States

Europe, Middle East & Africa
Josef-Schumpeter-Allee 33
53227 Bonn
Germany

Asia Pacific
50 Science Park Road, #01-01
The Kendall Science Park II
Singapore 117406

About Sirtex Medical

Sirtex Medical Limited (ASX:SRX) is an Australian-based global healthcare business working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer. Approximately 61,000 doses have been supplied to treat patients with liver cancer at more than 950 medical centres in over 40 countries. For more information please visit www.sirtex.com.

For further information please contact:

Investor Enquiries:

Mr Gilman Wong
CEO
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8400

Dr Tom Duthy
Global Investor Relations Manager
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8427
Email: tduthy@sirtex.com

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd